Cardiac Contractility Modulation (CCM) for Heart Failure (HF) | CMS Coverage Update

Summary: The Centers for Medicare & Medicaid Services modified its coverage policy for Cardiac Contractility Modulation (CCM) for Heart Failure, effective May 30, 2026. Here's what billing teams need to do.

CCM has been a moving target for reimbursement since the technology first landed on CMS's radar. This modification signals a meaningful shift in how the Centers for Medicare & Medicaid Services treats CCM coverage policy — and if your practice or facility implants these devices, your billing team needs to act before the May 30, 2026 effective date. The policy does not list specific CPT or HCPCS codes in the available data, but CCM device billing is complex enough that you should audit your current charge capture and documentation processes now, not after you receive your first post-modification claim denial.

Quick-Reference Table

CMS Cardiac Contractility Modulation Coverage Criteria and Medical Necessity Requirements 2026

CCM therapy works differently from traditional cardiac resynchronization therapy (CRT). It delivers non-excitatory electrical signals to the myocardium during the absolute refractory period — improving cardiac contractility without triggering depolarization. That distinction matters for billing because CMS has historically drawn a hard line between CCM and CRT coverage criteria, and this modification reinforces that CCM stands on its own medical necessity footing.

The real issue here is documentation. CMS coverage policy for CCM has always been tightly tied to patient-level criteria — ejection fraction thresholds, symptom class, prior therapy failure, and QRS duration. Failing to document any one of those elements at the time of implant creates a medical necessity gap that will generate a claim denial on audit, even if the clinical decision was sound.

The modified policy reflects CMS's ongoing scrutiny of CCM as a distinct therapeutic category. CMS does not treat CCM as interchangeable with cardiac resynchronization therapy, and your billing team should not treat them as interchangeable either. Document the specific clinical rationale for CCM over CRT in every operative note.

What Medical Necessity Typically Requires for CCM

Based on the established evidence base and CMS's prior coverage posture, CCM coverage for heart failure has centered on patients who meet all of the following:

If your patients don't clearly meet all of these criteria in the medical record, you have a medical necessity problem — not just a billing problem. Talk to your clinical documentation improvement team before May 30, 2026.

Prior Authorization Considerations

CMS itself does not administer prior authorization for most fee-for-service Medicare claims, but Medicare Advantage plans — which follow CMS coverage policy as a floor — do require prior authorization for CCM implant procedures. If your payer mix includes Medicare Advantage, check each plan's prior auth requirements against the updated CMS coverage policy. A modification at the CMS level often triggers corresponding updates in MA plan policies within 60–90 days.

CMS Cardiac Contractility Modulation Exclusions and Non-Covered Indications

CMS has consistently treated certain patient populations as outside the coverage boundary for CCM, and this modification does not appear to change that posture.

Atrial fibrillation: CCM clinical trials — particularly the FIX-HF-5C and CCM-REG data — have not demonstrated consistent benefit in AF patients. CMS's coverage policy has reflected this by treating AF as a contraindication rather than a relative exclusion.

QRS duration ≥ 130 ms: Patients who meet criteria for cardiac resynchronization therapy should be billed under CRT pathways. Billing CCM for a patient who qualifies for CRT is a misapplication of coverage criteria and creates significant claim denial risk.

Heart failure with preserved ejection fraction (HFpEF): CCM coverage under CMS has been limited to HFrEF. HFpEF patients represent a common documentation pitfall — if your cardiologist documents "heart failure" without specifying reduced ejection fraction and an actual LVEF value, the claim lacks the specificity CMS requires.

NYHA Class II or Class IV: Class II patients may not meet the symptom burden threshold. Class IV patients are generally excluded on safety grounds. Document NYHA class explicitly — don't let it sit buried in a clinical narrative where an auditor has to infer it.

Coverage Indications at a Glance

Note: The CMS policy modification does not list specific CPT or HCPCS codes in the available data. See the Affected Codes section below.

CMS Cardiac Contractility Modulation Billing Guidelines and Action Items 2026

This modification has real financial exposure for cardiology and electrophysiology groups. CCM implant procedures are high-dollar claims, and a single denial based on medical necessity documentation gaps is costly to work. Here's what to do before May 30, 2026.

CPT, HCPCS, and ICD-10 Codes for Cardiac Contractility Modulation Under This Policy

The CMS policy modification for Cardiac Contractility Modulation does not list specific CPT, HCPCS, or ICD-10 codes in the available policy data. Do not rely on assumed or inferred codes for CCM billing without confirming against the full policy text.

Access the full policy at the CMS source to obtain the complete code list: https://app.payerpolicy.org/p/cms/383-v1

For CCM billing in general, work with your billing consultant to confirm the correct device, implant, and follow-up codes currently recognized under CMS billing guidelines. CCM-specific coding has evolved as the technology gained broader acceptance, and the codes your team used in 2024 may not be the correct codes for claims filed after May 30, 2026.